Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LR-interferon beta
- Development stage
- Preclinical
- Lead developer
- ChromoLogic
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LR-interferon beta is a preclinical, engineered probiotic therapy in development by ChromoLogic for the treatment of gastrointestinal acute radiation syndrome (GI-ARS). [3] The drug consists of the bacterium *Limosilactobacillus reuteri*, which has been genetically modified to produce and release interferon-beta (IFN-β) within the gastrointestinal tract. [2] This localized delivery of IFN-β engages its corresponding signaling pathway to provide intestinal radioprotection and mitigation. [2, 4] Preclinical data indicates that LR-interferon beta preserves intestinal stem cells and improves the integrity of the intestinal barrier following radiation, ultimately enhancing survival. [2, 3, 4]
- Other names
- L. reuteri-IFN-β
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on LR-interferon beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LR-interferon beta.